Completed PHASE3 INTERVENTIONAL NCT00595374

Efficacy and Safety of Insulin Detemir in Type 1 Diabetes

Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart to Insulin NPH Plus Insulin Aspart in Adults With Type 1 Diabetes Mellitus

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 1

Interventions insulin NPH insulin aspart insulin detemir

Updated 7 times since 2017 Last updated: Feb 22, 2017 Started: Dec 2, 2003 Primary completion: Oct 7, 2004 Completion: Oct 7, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diabetes and Diabetes Mellitus, Type 1 and is currently completed. Novo Nordisk A/S leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Mar 2017 [monthly]

Completed PHASE3

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amersfoort, Netherlands , Apeldoorn, Netherlands , Den Helder, Netherlands , Deventer, Netherlands , Enschede, Netherlands , Gouda, Netherlands , Hoogeveen, Netherlands , Leidschendam, Netherlands , Meppel, Netherlands , Rotterdam, Netherlands and 7 more locations